๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group

โœ Scribed by Masaaki Kawahara; Yutaka Ariyoshi; Masahiro Fukuoka; Kiyoyuki Furuse

Publisher
Elsevier Science
Year
2000
Tongue
English
Weight
62 KB
Volume
36
Category
Article
ISSN
1040-8428

No coin nor oath required. For personal study only.

โœฆ Synopsis

The West Japan Lung Cancer Study Group (recently renamed the West Japan Thoracic Oncology Group) is a non-government, non-profit regional scientific organization whose objectives are to conduct clinical research and treatment of lung cancer, and to promote lung cancer expertise among thoracic physicians and radiologists in west Japan. Since 1990, a total of 46 institutes have joined and established the rules of a society. Our major interests are phase II and III trials of chemotherapy in lung cancer. We also have participated in activities with the Japan Clinical Oncology Group (JCOG), which is supported by the National Cancer Center in Tokyo. Additionally, we have conducted phase II and III trials with the support of Japanese pharmaceutical companies. This support allows us to conduct reliable, large-scale randomized trials. Our organization's main problems are unrefined data management and few qualified statisticians, due in part to a lack of funding.

๐Ÿ“œ SIMILAR VOLUMES

Originality, benefits and difficulties o
Originality, benefits and difficulties of clinical research performed by cooperative groups: the experience of an Italian Lung Cancer Study Group
โœ C. Gridelli; B. Daniele ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› Elsevier Science ๐ŸŒ English โš– 75 KB

In the past years, clinical research performed by cooperative groups achieved important results. The trials of adjuvant chemotherapy in breast and colorectal cancer or neoadjuvant treatment in osteosarcoma are cornerstones in the history of medical oncology and highlight the importance of research p

UICC study group in basic and clinical c
UICC study group in basic and clinical cancer research: Genomic changes and the origin of neoplasia
โœ Ruth Sager ๐Ÿ“‚ Article ๐Ÿ“… 1985 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 393 KB ๐Ÿ‘ 1 views

## Ruth SAGER The second Study Group Meeting on basic and clinical cancer research was organized to consider the origin and the regulation of genomic changes in neoplasia. At a previous UICC Workshop in 1979, the evidence presented of non-random chromosome aberrations in neoplastic cells was both

Concordance of histological classificati
Concordance of histological classification of lung cancer with special reference to adenocarcinoma in osaka, japan, and the north-west region of england
โœ A. Hanai; J. S. Whittaker; R. Tateishi; L. H. Sobin; R. T. Benn; C. S. Muir ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 443 KB ๐Ÿ‘ 1 views

In routinely collected data adenocarcinoma of the lung appeared to be 3 times more frequent in Osaka, Japan, than in the North-Western (NW) Region of England (Manchester). Before embarking on comparative epidemiological studies, it was decided to investigate the comparability of histological diagnos

Dose escalation study of carboplatin wit
Dose escalation study of carboplatin with fixed-dose etoposide plus granulocyte-colony stimulating factor in patients with small cell lung carcinoma: A study of the lung cancer study group of west Japan
โœ Nobuyuki Katakami; Minoru Takada; Shunichi Negoro; Katsuyasu Ota; Jiro Fujita; K ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 738 KB

## BACKGROUND. We performed a Phase 1-11 trial to determine the maximum tolerated dose of carboplatin (CBDCA) with a fixed dose of VP-16 and granulocyte-colony stimulating factor (G-CSF) in small cell lung cancer (SCLC) patients. ## METHODS. Treatment consisted of a starting dose of CBDCA, 400